VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vericel Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$40.37+0.24 (+0.60%)
Close on Oct 19, 2026
- Market cap
- $2.11B
- P/E (TTM)
- 96.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
56M of 51M shares
Institutional holders
319
66 new, 22 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 34 sales
Net sold $7.89M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,570,280 | 15.10% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 2,807,242 | 5.60% | 13G (passive) | Sep 30, 2025 |
| Vanguard Capital Management | 2,603,128 | 5.11% | 13G (passive) | Mar 31, 2026 |
| Soleus Capital, LLC | 2,549,079 | 5.00% | 13G (passive) | Mar 31, 2026 |
| Conestoga Capital Advisors LLC | 2,495,619 | 5.23% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VCEL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,092,226 | 15.80% | $360.02M | +326,882 | 0.01% |
| State Street Corp | 3,293,975 | 6.43% | $146.58M | +141,845 | 0.00% |
| Congress Asset Management Co /Ma | 2,916,295 | 5.70% | $129.75M | +1,409,377 | 0.80% |
| Vanguard Capital Management LLC | 2,255,728 | 4.41% | $100.36M | +24,972 | 0.00% |
| Conestoga Capital Advisors, LLC | 2,083,832 | 4.07% | $92.71M | −379,480 | 2.02% |
| William Blair Investment Management, LLC | 1,992,855 | 3.89% | $88.66M | +160,146 | 0.27% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,639,988 | 3.20% | $72.96M | −83,584 | 0.07% |
| GW&K Investment Management, LLC | 1,550,497 | 3.03% | $68.98K | −66,358 | 0.54% |
| Soleus Capital Management, L.P. | 1,459,152 | 2.85% | $64.92M | −1,089,927 | 2.24% |
| Geode Capital Management, LLC | 1,341,244 | 2.62% | $59.68M | +86,382 | 0.00% |
| Geneva Capital Management LLC | 1,339,123 | 2.62% | $59.58M | −307,695 | 1.37% |
| Loomis Sayles & Co L P | 1,200,239 | 2.34% | $53.40M | +224,792 | 0.07% |
| Vanguard Portfolio Management LLC | 1,060,753 | 2.07% | $47.19M | +69,127 | 0.00% |
| Bank Of America Corp /De/ | 1,016,184 | 1.98% | $45.21M | −82,587 | 0.00% |
| Dimensional Fund Advisors LP | 906,200 | 1.77% | $40.32M | +61,445 | 0.01% |
| Silvercrest Asset Management Group LLC | 896,651 | 1.75% | $39.89M | −62,556 | 0.26% |
| Royal Bank of Canada | 775,762 | 1.51% | $34.51M | −106,400 | 0.01% |
| Champlain Investment Partners, LLC | 755,828 | 1.48% | $33.63M | −59,345 | 0.86% |
| abrdn plc | 710,238 | 1.39% | $31.60M | +26,113 | 0.04% |
| Nomura Asset Management International Inc. | 664,305 | 1.30% | $29.56M | +33,426 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 319 | 56M | 100.0% | 66 / 121 | 100 / 22 | 7M | 6M |
| Q1 2026 | 279 | 55M | 100.0% | 41 / 105 | 97 / 31 | 11M | 6M |
| Q4 2025 | 273 | 54M | 100.0% | 55 / 100 | 81 / 27 | 6M | 6M |
| Q3 2025 | 250 | 53M | 100.0% | 29 / 86 | 98 / 47 | 5M | 8M |
| Q2 2025 | 273 | 56M | 100.0% | 35 / 130 | 69 / 36 | 7M | 4M |
| Q1 2025 | 277 | 54M | 100.0% | 32 / 114 | 92 / 29 | 4M | 2M |
| Q4 2024 | 278 | 52M | 100.0% | 44 / 102 | 85 / 30 | 4M | 3M |
| Q3 2024 | 268 | 51M | 100.0% | 32 / 102 | 90 / 23 | 12M | 4M |
| Q2 2024 | 261 | 51M | 99.8% | 37 / 95 | 92 / 29 | 4M | 5M |
| Q1 2024 | 257 | 53M | 100.0% | 50 / 83 | 87 / 20 | 6M | 7M |
| Q4 2023 | 227 | 54M | 100.0% | 31 / 60 | 96 / 15 | 4M | 2M |
| Q3 2023 | 213 | 51M | 100.0% | 28 / 77 | 77 / 17 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VCEL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3,077,197 | 6.01% | $136.90M | 0.12% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,617,188 | 3.16% | $71.95M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,337,684 | 2.61% | $59.51M | 0.07% | Jun 30, 2026 |
| Conestoga Small Cap Fund | 1,307,355 | 2.55% | $58.16M | 2.85% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,194,313 | 2.33% | $53.13M | 0.49% | Jun 30, 2026 |
| Congress Small Cap Growth Fund | 1,090,000 | 2.13% | $50.10M | 2.49% | Jul 31, 2026 |
| Loomis Sayles Small Cap Growth Fund | 649,165 | 1.27% | $28.88M | 1.27% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 583,754 | 1.14% | $25.97M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 563,199 | 1.10% | $25.88M | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 475,914 | 0.93% | $21.17M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 469,549 | 0.92% | $20.89M | 0.12% | Jun 30, 2026 |
| William Blair Small Cap Growth Fund | 469,354 | 0.92% | $20.88M | 1.70% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 459,063 | 0.90% | $20.42M | 0.25% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 406,549 | 0.79% | $18.09M | 1.54% | Jun 30, 2026 |
| Brown Capital Management Small Company Fund | 373,015 | 0.73% | $16.60M | 5.17% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dominick Colangelo | President and CEO, Director | 321,270 | 0.63% | Feb 26, 2026 |
| Michael Halpin | Chief Operating Officer | 32,753 | 0.06% | Aug 5, 2026 |
| Jonathan Siegal | Principal Accounting Officer | 1,078 | 0.00% | Jul 31, 2026 |
| Jonathan Mark Hopper | Chief Medical Officer | 75,753 | 0.15% | Jun 30, 2026 |
| Joseph Anthony Mara Jr | Chief Financial Officer | 16,009 | 0.03% | Jun 30, 2026 |
| Sean C. Flynn | Chief Legal Officer | 1,647 | 0.00% | Jun 30, 2026 |
| Karen Mahoney | Chief Human Resources Officer | 2,625 | 0.01% | Dec 12, 2025 |
| Kevin F. McLaughlin | Director | 18,300 | 0.04% | Aug 14, 2026 |
| Paul K. Wotton | Director | 26,302 | 0.05% | May 13, 2026 |
| Alan L. Rubino | Director | 64,234 | 0.13% | May 1, 2026 |
| Robert L. Zerbe Md | Director | 32,995 | 0.06% | May 1, 2026 |
| Lisa Wright | Director | 15,851 | 0.03% | May 1, 2026 |
| Heidi Hagen | Director | 35,050 | 0.07% | May 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kevin F. McLaughlin Director | Aug 12, 2026 | Sale(10b5-1 plan) | −7,000 | $44.53 | $311.71K | 18,300 |
| Kevin F. McLaughlin Director | Aug 12, 2026 | Option exercise | +7,000 | $13.05 | $91.35K | 25,300 |
| Michael Halpin Chief Operating Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −10,000 | $46.84 | $468.40K | 16,394 |
| Michael Halpin Chief Operating Officer | Aug 3, 2026 | Option exercise | +10,000 | $16.66 | $166.60K | 26,394 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −500 | $48.90 | $24.45K | 1,078 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Option exercise | +1,500 | $34.90 | $52.35K | 2,578 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −1,500 | $48.90 | $73.35K | 1,078 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Option exercise | +2,500 | $29.82 | $74.55K | 3,578 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −2,500 | $48.90 | $122.25K | 1,078 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Option exercise | +500 | $29.82 | $14.91K | 1,578 |
| Jonathan Siegal Principal Accounting Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −232 | $44.90 | $10.42K | 886 |
| Jonathan Siegal Principal Accounting Officer | Jun 26, 2026 | Option exercise | +2,500 | $29.82 | $74.55K | 3,386 |
| Jonathan Siegal Principal Accounting Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −2,500 | $44.90 | $112.25K | 886 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,000 | $45.00 | $225.00K | 75,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Option exercise | +5,000 | $29.82 | $149.10K | 80,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,000 | $45.00 | $225.00K | 75,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Option exercise | +5,000 | $29.82 | $149.10K | 80,753 |
| Joseph Anthony Mara Jr Chief Financial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,000 | $44.75 | $223.75K | 16,009 |
| Sean C. Flynn Chief Legal Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −15,000 | $45.64 | $684.60K | 1,647 |
| Sean C. Flynn Chief Legal Officer | Jun 26, 2026 | Option exercise | +15,000 | $16.25 | $243.75K | 16,647 |
| Michael Halpin Chief Operating Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −10,000 | $40.24 | $402.40K | 16,248 |
| Michael Halpin Chief Operating Officer | Jun 18, 2026 | Option exercise | +10,000 | $16.66 | $166.60K | 26,248 |
| Sean C. Flynn Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −15,000 | $40.21 | $603.15K | 1,647 |
| Sean C. Flynn Chief Legal Officer | Jun 18, 2026 | Option exercise | +15,000 | $16.25 | $243.75K | 16,647 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −4,375 | $35.00 | $153.13K | 75,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 2, 2026 | Option exercise | +4,375 | $16.66 | $72.89K | 80,128 |
| Kevin F. McLaughlin Director | May 13, 2026 | Sale(10b5-1 plan) | −3,500 | $32.82 | $114.87K | 18,300 |
| Kevin F. McLaughlin Director | May 13, 2026 | Option exercise | +3,500 | $2.63 | $9.21K | 21,800 |
| Kevin F. McLaughlin Director | May 13, 2026 | Sale(10b5-1 plan) | −3,500 | $32.83 | $114.91K | 18,300 |
| Kevin F. McLaughlin Director | May 13, 2026 | Option exercise | +3,500 | $13.05 | $45.68K | 21,800 |
| Paul K. Wotton Director | May 11, 2026 | Sale | −2,500 | $33.05 | $82.63K | 26,302 |
| Paul K. Wotton Director | May 11, 2026 | Sale | −7,500 | $32.64 | $244.80K | 18,802 |
| Jonathan Siegal Principal Accounting Officer | May 7, 2026 | Sale(10b5-1 plan) | −1,422 | $40.50 | $57.59K | 1,118 |
| Joseph Anthony Mara Jr Chief Financial Officer | May 7, 2026 | Sale(10b5-1 plan) | −5,000 | $40.50 | $202.50K | 21,009 |
| Jonathan Siegal Principal Accounting Officer | May 6, 2026 | Sale(10b5-1 plan) | −3,433 | $38.00 | $130.45K | 2,540 |
| Lisa Wright Director | Apr 29, 2026 | Option exercise | +3,200 | – | – | 15,851 |
| Kevin F. McLaughlin Director | Apr 29, 2026 | Option exercise | +3,200 | – | – | 18,300 |
| Alan L. Rubino Director | Apr 29, 2026 | Option exercise | +3,200 | – | – | 64,194 |
| Heidi Hagen Director | Apr 29, 2026 | Option exercise | +3,200 | – | – | 35,050 |
| Paul K. Wotton Director | Apr 29, 2026 | Option exercise | +3,200 | – | – | 28,802 |
| Robert L. Zerbe Md Director | Apr 29, 2026 | Option exercise | +3,200 | – | – | 32,995 |
| Jonathan Mark Hopper Chief Medical Officer | Apr 2, 2026 | Option exercise | +3,472 | $10.95 | $38.02K | 79,028 |
| Jonathan Mark Hopper Chief Medical Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −3,472 | $35.00 | $121.52K | 75,556 |
| Alan L. Rubino Director | Mar 25, 2026 | Option exercise | +15,000 | $2.76 | $41.40K | 60,994 |
| Heidi Hagen Director | Mar 23, 2026 | Option exercise | +15,000 | $2.76 | $41.40K | 46,850 |
| Heidi Hagen Director | Mar 23, 2026 | Sale(10b5-1 plan) | −15,000 | $32.41 | $486.15K | 31,850 |
| Michael Halpin Chief Operating Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −10,305 | $35.30 | $363.77K | 16,080 |
| Sean C. Flynn Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −6,421 | $34.75 | $223.13K | 1,262 |
| Sean C. Flynn Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −15,000 | $35.36 | $530.40K | 1,262 |
| Sean C. Flynn Chief Legal Officer | Mar 2, 2026 | Option exercise | +15,000 | $16.25 | $243.75K | 16,262 |
| Sean C. Flynn Chief Legal Officer | Feb 24, 2026 | Option exercise | +3,000 | – | – | 9,014 |
| Sean C. Flynn Chief Legal Officer | Feb 24, 2026 | Option exercise | +3,500 | – | – | 7,567 |
| Sean C. Flynn Chief Legal Officer | Feb 24, 2026 | Tax withholding | −1,331 | $38.25 | $50.91K | 7,683 |
| Sean C. Flynn Chief Legal Officer | Feb 24, 2026 | Tax withholding | −1,553 | $38.09 | $59.15K | 6,014 |
| Dominick Colangelo President and CEO, Director | Feb 24, 2026 | Option exercise | +18,250 | – | – | 321,270 |
| Dominick Colangelo President and CEO, Director | Feb 24, 2026 | Option exercise | +18,250 | – | – | 303,020 |
| Dominick Colangelo President and CEO, Director | Feb 24, 2026 | Tax withholding | −8,824 | $38.09 | $336.11K | 312,446 |
| Jonathan Mark Hopper Chief Medical Officer | Feb 24, 2026 | Option exercise | +350 | – | – | 71,377 |
| Jonathan Mark Hopper Chief Medical Officer | Feb 24, 2026 | Option exercise | +1,500 | – | – | 76,192 |
| Jonathan Mark Hopper Chief Medical Officer | Feb 24, 2026 | Option exercise | +1,500 | – | – | 74,692 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kevin F. McLaughlin Director | Aug 12, 2026 | 7,000 | $308.77K | Aug 12, 2026 | Stock Option Exercise |
| Michael Halpin Officer | Aug 3, 2026 | 10,000 | $459.80K | Aug 3, 2026 | Stock Option Exercise |
| Jonathan Siegal Officer | Jul 30, 2026 | 4,500 | $220.05K | Jul 30, 2026 | Stock Option Exercise |
| Sean C. Flynn Officer | Jun 26, 2026 | 15,000 | $684.66K | Jun 26, 2026 | Stock Option Exercise |
| Joseph Anthony Mara Jr Officer | Jun 26, 2026 | 5,000 | $223.75K | Jun 26, 2026 | Restricted Stock Vesting |
| Jonathan Siegal Officer | Jun 26, 2026 | 2,732 | $122.67K | Jun 26, 2026 | Restricted Stock Vesting |
| Jonathan Mark Hopper Officer | Jun 26, 2026 | 10,000 | $450.00K | Jun 26, 2026 | Stock Option Exercise |
| Sean C. Flynn Officer | Jun 18, 2026 | 15,000 | $603.15K | Jun 18, 2026 | Stock Option Exercise |
| Michael Halpin Officer | Jun 18, 2026 | 10,000 | $402.40K | Jun 18, 2026 | Stock Option Exercise |
| Jonathan Mark Hopper Officer | Jun 2, 2026 | 4,375 | $153.13K | Jun 2, 2026 | Option Granted - 02/06/2019 |
| Kevin F. McLaughlin Director | May 13, 2026 | 7,000 | $227.99K | May 13, 2026 | Option Granted - 05/03/2017 |
| Paul K. Wotton Director | May 11, 2026 | 10,000 | $327.43K | May 11, 2026 | stock option exercise |
| Joseph Anthony Mara Jr Officer | May 7, 2026 | 5,000 | $202.50K | May 7, 2026 | Restricted Stock Vesting |
| Jonathan Siegal Officer | May 7, 2026 | 1,422 | $57.59K | May 7, 2026 | ESPP Purchase |
| Jonathan Siegal Officer | May 6, 2026 | 3,433 | $130.45K | May 6, 2026 | Restricted Stock Vesting |